Accord BioPharma announced today the commercial launch of discounted, prefilled syringes of Imuldosa (ustekinumab-srlf), a Stelara (ustekinumab) biosimilar, according to a news release.

Imuldosa is supplied as a single-dose prefilled syringe for subcutaneous use in 45 mg/0.5 mL and 90 mg/mL strengths or as a single-dose vial for intravenous infusion in 130 mg/26 mL. The prefilled syringes of Imuldosa are priced at a 92% discount from Stelara, making it the lowest wholesaler acquisition cost (WAC) among all branded ustekinumab biosimilars. The vial formulations are offered at a 33% discount. Accord BioPharma will also launch a $0 co-pay Imuldosa program for eligible patients, according to the news release.

Biosimilars are biologic medicines that are highly similar to an already approved

See Full Page